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Abstract ABCA1-deficient mice have low levels of poorly
lipidated apolipoprotein E (apoE) and exhibit increased am-
yloid load. To test whether excess ABCA1 protects from
amyloid deposition, we crossedAPP/PS1mice toABCA1bac-
terial artificial chromosome (BAC) transgenic mice. Com-
pared with wild-type animals, the ABCA1 BAC led to a 50%
increase in cortical ABCA1 protein and a 15% increase in
apoE abundance, demonstrating that this BAC supports
modest ABCA1 overexpression in brain. However, this was
observed only in animals that do not deposit amyloid. Com-
parison of ABCA1/APP/PS1 mice with APP/PS1 controls
revealed no differences in levels of brain ABCA1 protein,
amyloid, Ab, or apoE, despite clear retention of ABCA1
overexpression in the livers of these animals. To further
investigate ABCA1 expression in the amyloid-containing
brain, we then compared ABCA1 mRNA and protein levels
in young and aged cortex and cerebellum of APP/PS1 and
ABCA1/APP/PS1 animals. Compared with APP/PS1 controls,
aged ABCA1/APP/PS1 mice exhibited increased ABCA1
mRNA, but not protein, selectively in cortex. Additionally,
ABCA1 mRNA levels were not increased before amyloid
deposition but were induced only in the presence of exten-
sive Ab and amyloid levels. These data suggest that an
induction of ABCA1 expression may be associated with late-
stage Alzheimer’s neuropathology.—Hirsch-Reinshagen, V.,
J. Y. Chan, A. Wilkinson, T. Tanaka, J. Fan, G. Ou, L. F.
Maia, R. R. Singaraja, M. R. Hayden, and C. L. Wellington.
Physiologically regulated transgenic ABCA1 does not re-
duce amyloid burden or Ab peptide levels in vivo. J. Lipid
Res. 2007. 48: 914–923.
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Apolipoprotein E (apoE) is a well-validated risk factor
for late-onset Alzheimer’s disease (AD) (1). In the central
nervous system (CNS), apoE is secreted by astrocytes and
microglia and serves as the major cholesterol carrier in
brain (2). ApoE also binds amyloid-b peptide (Ab) and is
found in amyloid plaques (3, 4). ApoE-deficient mice de-
posit Ab but not amyloid, (5, 6), and the extent of amyloid
deposition correlates with apoE gene dose (7). These find-
ings suggest that factors that regulate apoE abundance
may affect amyloidogenesis.
We and others have shown that ABCA1 modulates CNS
apoE levels (8–10). ABCA1 effluxes cellular lipids onto
lipid-poor apolipoprotein acceptors (11), and deficiency
of ABCA1 results in nearly undetectable plasma HDL lev-
els, impaired cholesterol efflux, and an increased risk of
cardiovascular disease (12–14). In the brain, ABCA1 is ex-
pressed in neurons, astrocytes, and microglia and is in-
duced by liver X receptor (LXR) and retinoic X receptor
(RXR) agonists (15–18). ABCA1-deficient glia secrete less
apoE than wild-type cells and are impaired in cholesterol
efflux to apoE (8). These effects may underlie the drastic
reduction in CNS apoE levels found in ABCA1-deficient
mice and explain the poor lipidation of the remaining
apoE particles (8–10).
Recently, we and others demonstrated that ABCA1 also
modulates amyloid burden in vivo (19–21). Because apoE
levels correlate with the extent of amyloid load, the reduced
levels of apoE in ABCA1-deficient mice led to the predic-
tion that fewer amyloid deposits would be observed in the
absence of ABCA1. In contrast, ABCA1-deficient mice de-
veloped an equal or greater amyloid burden than wild-type
mice in four independent models of AD (19–21), dem-
onstrating that poorly lipidated apoE markedly promotes
amyloidogenesis. These observations raise the converse
possibility that selective overexpression of ABCA1 may en-
hance apoE lipidation and lead to reduced amyloid levels.
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To test this possibility, we crossed the APP/PS1 mouse
model of AD to ABCA1 bacterial artificial chromosome
(BAC) transgenic (Tg) mice, which express human ABCA1
from endogenous regulatory signals (22). BAC Tg models
are desirable for many in vivo investigations, as the trans-
gene is expressed from physiologically relevant regulatory
elements that conserve appropriate developmental and
tissue-specific expression patterns (23). Accordingly, ex-
pression of human ABCA1 from a BAC transgene has been
shown to mirror that of endogenous murine abca1 in mul-
tiple tissues, including brain (24), and protects from ath-
erosclerosis in both whole animal and bone marrow
transplant paradigms (25, 26).
Here, we report that although the ABCA1 BAC leads to
modestly increased ABCA1 protein levels in brain, this is
observed only in animals without amyloid deposits. In an-
imals with advanced AD neuropathology, ABCA1 protein
levels are not increased by the presence of the ABCA1
BAC, even though human and murine ABCA1 mRNA lev-
els are both increased. Accordingly, no changes in amy-
loid, apoE, or Ab levels are found between APP/PS1 mice
in the absence or presence of human ABCA1. These ob-
servations suggest that the expression of ABCA1 may be
subject to transcriptional and posttranscriptional control
in brain with advanced AD, which ultimately may attenu-
ate ABCA1 protein accumulation in vivo.
MATERIALS AND METHODS
Animals
ABCA1 BAC Tg mice containing BAC RP11-32H03 have been
described previously (27) and are maintained on a congenic
C57Bl/6 genetic background. APP/PS1 (line 85) mice (Jackson
Laboratories, Bar Harbor, ME) express a chimeric mouse/human
APP650 cDNA containing the Swedish (KM670/671NL) mutation
cointegrated with the human presenilin 1 (PS1) gene containing
the DE9 mutation (28) and are maintained on an F1 50% C3H,
50% C57Bl/6 genetic background. APP/PS1 mice were crossed to
ABCA1 BAC Tg animals, and double ABCA1/APP/PS1 Tg animals
were compared with APP/PS1 littermate controls, all with a 75%
C57Bl/6, 25%C3H genetic composition. Animals weremaintained
on a chow diet (PMI LabDiet 5010), and all animal procedures
were in accordance with the Canadian Council of Animal Care and
the University of British Columbia Committee on Animal Care.
Protein extraction and Western blot
Murine tissue extractions were performed as described pre-
viously (19). Briefly, brain regions were homogenized in ice-cold
PBS containing Complete protease inhibitor (Roche, Mississauga,
Canada) in a Tissuemite homogenizer followed by centrifugation.
The supernatant (soluble fraction) was then removed and used to
evaluate soluble apoE. The pellets from the PBS solubilization step
were resuspended in ice-cold lysis buffer containing 10% glycerol,
1% Triton X-100, and Complete protease inhibitor (Roche) in
PBS and centrifuged to extract ABCA1. The pellet from this step
(insoluble fraction) was finally solubilized in 5 M guanidine hy-
drochloride in 50 mM Tris-HCl, pH 8.0, to evaluate plaque-
associated Ab. Brain tissues from all animals were extracted in an
identical manner, and all fractions were immediately frozen at
280jC until analysis. Liver tissues were homogenized directly into
ice-cold lysis buffer containing 10% glycerol, 1%TritonX-100, and
Complete protease inhibitor (Roche) in PBS. Protein concentra-
tions were determined by DC Protein Assay (Bio-Rad, Hercules,
CA). For Western blots, tissue lysates were resolved by SDS-PAGE
and immunodetected using a monoclonal anti-ABCA1 antibody
(AC10) (16) or an anti-GAPDH antibody (Chemicon, Temecula,
CA) as a loading control. Blots were developed using enhanced
chemiluminescence (Amersham, Piscataway, NJ) and quantified
using NIH Image J software.
ApoE ELISA
Murine apoE levels were determined by ELISA as described
previously (9). Plates were coated with anti-apoE (WUE-4) (a kind
gift from D. Holtzman, Washington University). Samples were di-
luted in 0.5% BSA and 0.025% Tween-20 in PBS. Standards were
based on plasma from Swiss-Webster rats containing 61.7 mg/ml
apoE (9). After an overnight incubation at 4jC, plates were incu-
bated with goat anti-apoE (EMD Biosciences, San Diego, CA) fol-
lowed by biotinylated anti-goat antibody (Vector Laboratories,
Burlington, CA). Plates were developed with poly-horseradish
peroxidase streptavidin (Pierce, Rockford, IL) and ultra-slow
3,3¶,5,5¶-tetramethylbenzidine (Sigma, St. Louis, MO), stopped
with 1 N HCl, and read at 450 nm.
Cerebrospinal fluid cholesterol measurements
Cerebrospinal fluid (CSF) was isolated as described previously
(29). Total cholesterol measurements were performed using the
fluorogenic Amplex RedCholesterol Assay Kit (Molecular Probes,
Burlington, CA).
Neuropathological analyses
Thioflavine-S staining of amyloid plaques was performed and
quantified as described (19). Human Ab levels were quantified by
ELISA (Biosource, Camarillo, CA) and normalized to total protein.
Quantitative RT-PCR
RNAwas extracted using Trizol (Invitrogen, Burlington, CA) and
treated with DNaseI. cDNA was generated using oligo-dT primers
and Taqman reverse transcription reagents (Applied Biosystems,
Foster City, CA). Quantitative real-time PCR primers were designed
using PrimerExpress (Applied Biosystems) to span human- and
murine-specific regions of ABCA1 or regions identical in both spe-
cies. Primer sequences and cycling conditions will be provided upon
request. Real-time quantitative PCR was done with SYBR Green re-
agents (Applied Biosystems) on an ABI 7000 (Applied Biosystems).
Each sample was assayed at least in duplicate, normalized to b-actin,
and analyzed with 7000 system SDS software version 1.2 (Applied
Biosystems) using the relative standard curve method.
Statistical analysis
Data are shown as means 6 SEM and were analyzed by two-
tailed unpaired Student’s t-tests for comparisons between two
groups or by one-way ANOVA with a Newman-Keul’s posttest for
comparisons among multiple groups. Welch’s correction for un-
equal variances was applied when variances were significantly
different between groups. Analyses were performed using Graph-
Pad Prism (version 4.0; GraphPad, San Diego, CA).
RESULTS
ABCA1 and apoE levels are increased in cortex of ABCA1
BAC Tg mice
To test whether excess ABCA1 can mitigate amyloid de-
position, ABCA1 BAC Tg mice were crossed to the APP/
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PS1 model of AD, resulting in four groups of animals con-
sisting of wild type, ABCA1 BAC, APP/PS1, and ABCA1/
APP/PS1 littermates that are optimally matched for their
mixed (75% C57Bl/6, 25% C3H) genetic background. To
first validate the ABCA1 BAC Tg model for this study, we
confirmed that the presence of the ABCA1 BAC transgene
resulted in increased ABCA1 levels in adult brain (in ani-
mals of 14.5 6 1.35 months of age). Compared with wild-
type animals, ABCA1 protein levels were increased by
?50% in ABCA1 BAC Tg cortex and by ?100% in liver
(cortex, P 5 0.0009, n > 13; liver, P 5 0.0042, n 5 8)
(Fig. 1A). These values represent the sum of both human
and murine ABCA1 protein, as our ABCA1 antibody does
not distinguish between human and murine ABCA1. That
human ABCA1 expression was considerably more robust in
the liver compared with the brain suggests that the endog-
enous regulatory sequences present on BAC RP11-23H03
are less efficiently recognized in brain, that BAC RP11-
23H03 may be missing some elements required for robust
expression in cells in the CNS, or that ABCA1 may be ex-
pressed in a greater proportion of total cells in liver com-
pared with brain.
We next determined whether increased brain ABCA1
resulted in increased cortical and CSF apoE levels and CSF
cholesterol (Fig. 1B). Consistent with the modest degree
of ABCA1 overexpression in the BAC Tgmice, PBS-soluble
apoE levels were slightly, but significantly, increased by
15% in the cortex of ABCA1 BAC Tg mice (mean apoE
level 5 185.1 ng/mg) compared with wild-type controls
(mean apoE level 5 160.9 ng/mg) (P 5 0.036, n > 12).
However, no significant changes were observed in either
CSF apoE levels or CSF cholesterol in the presence of
ABCA1 overexpression. These data show that physiological
overexpression of ABCA1 protein in the BAC Tg model is
sufficient to promote a subtle increase in apoE levels
in brain tissue but is unable to alter the levels or lipidation
of circulating apoE in CSF, where particles are subject
to remodeling.
Amyloid burden and Ab and apoE levels are not changed
by the presence of physiologically regulated
human ABCA1
To determine whether excess ABCA1 may inhibit amy-
loidogenesis in vivo, we then analyzed APP/PS1 mice with
and without the ABCA1 BAC at 14.5 months of age. No
significant differences in amyloid burden, guanidine-
extractable Ab levels, soluble apoE levels, or CSF choles-
terol were observed between ABCA1/APP/PS1 Tg animals
(APP/BAC1) relative to APP/PS1 littermate controls
(APP/BAC2) (Fig. 2). These data show that physiologi-
cally regulated expression of human ABCA1 from endog-
enous regulatory elements present on BAC RP11-32H03
does not significantly affect Ab or apoE metabolism in vivo
in aged APP/PS1 mice.
Human ABCA1 is expressed in brain and liver of ABCA1/
APP/PS1 mice but makes a significant contribution to
total ABCA1 protein levels only in liver
To determine whether the inability to detect a change
in amyloid, Ab, apoE, or CSF cholesterol in the ABCA1/
APP/PS1 mice could be attributed to an unexpected loss
of ABCA1 expression from the BAC, quantitative RT-PCR
was used to quantify human, murine, and total ABCA1
mRNA of ABCA1/APP/PS1 (APP/BAC1) mice compared
with APP/PS1 littermates (APP/BAC2). Validation tests
first confirmed that the human primers were unable to
amplify murine abca1 mRNA and that the murine primers
did not amplify human ABCA1 mRNA (data not shown).
As expected, human ABCA1 mRNA was present only in
Fig. 1. The ABCA1 bacterial artificial chromosome
(BAC) increases cortical and liverABCA1andcortical apo-
lipoprotein E (apoE) levels but does not affect cerebro-
spinal fluid (CSF) apoE or cholesterol. A: Total ABCA1
protein in cortex and liver was measured by Western
blot and quantitated by densitometry relative to GAPDH
levels. Graphs are expressed as percentage of wild-type
levels (wild-type animals were assigned a 100% level) and
illustrate the pooled results of four independentmeasure-
ments of 14wild-type (WT) and 13ABCA1BAC transgenic
(Tg) (BAC1) cortical samples and at least two indepen-
dent measurements of 8 wild-type and 8 ABCA1 BAC Tg
liver samples. Values shown are means 6 SEM. B: Left
panel: PBS-soluble cortical apoE levels were measured
by ELISA and normalized for total protein. The graph
represents two independent experiments of 13 wild-type
(WT) and 12 ABCA1 BAC Tg (BAC1) samples measured
in triplicate. Middle panel: CSF apoE levels were assessed
by ELISA. The graph represents 14 wild-type (WT) and
9 ABCA1 BACTg (BAC1) samples. Right panel: CSF total
cholesterol was analyzed using the Amplex Red Cholesterol
Assay Kit. The graph represents 13 wild-type (WT) and
9 ABCA1 BAC Tg (BAC1) samples. Two-tailed Student’s
t-tests were used for statistical analyses.
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animals carrying the ABCA1 BAC transgene (Fig. 3A), and
murine abca1 mRNA levels were similar in ABCA1/APP/
PS1 (APP/BAC1) compared with APP/PS1 (APP/BAC2)
mice, showing that the presence of the human ABCA1
BAC transgene has no significant influence on murine
abca1 mRNA levels (Fig. 3B). Surprisingly, we observed no
increase in total ABCA1 mRNA (P . 0.05, n > 6) or
protein (P . 0.05, n > 10) levels in cortical extracts pre-
pared from APP/PS1 (APP/BAC2) and ABCA1/APP/PS1
(APP/BAC1) mice (Fig. 3C–E), suggesting that the hu-
man ABCA1 BAC makes a negligible contribution to total
ABCA1 in the amyloid-containing brain.
ABCA1 expression was also evaluated in the liver of these
samemice. As expected, humanABCA1mRNAwas detected
only inanimals carrying theABCA1BACtransgene (Fig. 4A),
and murine abca1 mRNA levels were no different between
groups (Fig. 4B).Unlikebrain, however, totalABCA1mRNA
and protein levels were increased by ?2-fold in ABCA1/
APP/PS1 livers (APP/BAC1) compared with APP/PS1 con-
trols (APP/BAC2) (P50.0345,n>5 formRNA,P50.0003,
n 5 8 for protein) (Fig. 4D, E). These results demonstrate
that the human BAC remains functional after breeding to
APP/PS1 mice but that its expression in brain may be al-
tered in mice with amyloid deposits.
ABCA1 mRNA but not protein levels are increased in the
amyloid-containing brain
To further explore these findings, we then compared
ABCA1 mRNA and protein levels in cortex and cerebel-
lum in littermate mice of all four genotypes. Compared
with wild-type mice, murine abca1 mRNA levels were in-
creased significantly in the cortex of APP/PS1 (APP/BAC2)
(P , 0.05, n 5 8) and ABCA1/APP/PS1 (APP/BAC1)
(P , 0.05, n 5 6) mice but were unchanged in cerebel-
lum (P . 0.05, n . 7) (Fig. 5A). Similarly, human ABCA1
mRNA levels were ?3-fold higher in cortex (P , 0.05,
n> 6) but not in cerebellum (P. 0.05, n> 7) of ABCA1/
APP/PS1 (APP/BAC1) compared with ABCA1 BAC Tg
(BAC1) mice (Fig. 5B). However, this increase in cortical
ABCA1 mRNA was not necessarily accompanied by a pro-
portional increase of ABCA1 protein. Compared with wild-
type mice, animals with the ABCA1 BAC alone or with the
APP/PS1 transgenes alone each displayed a very modest
but significant increase of total ABCA1 protein in cortex
(P , 0.01, n > 10, each group compared with wild-type
controls) (Fig. 5C). However, compared with APP/PS1
(APP/BAC2) mice, ABCA1/APP/PS1 (APP/BAC1) mice
displayed no further increase in cortical ABCA1 protein
levels, despite having significantly increased murine and
Fig. 2. ABCA1 BAC transgene expression has no significant effect on amyloid burden, Ab level, apoE
abundance, or CSF cholesterol. A: Thioflavine-S staining of hemicoronal sections from APP/PS1 hip-
pocampi in the presence (APP/BAC1) and absence (APP/BAC2) of the ABCA1 BAC transgene. Images
show two individual mice per genotype and correspond to 2.53 magnification of the hippocampus. Bar 5
1,000 mm. Amyloid load was quantitated for hippocampus and cingulate cortex in six APP/PS1
(APP/BAC2) and six ABCA1/APP/PS1 (APP/BAC1) animals. B: The graph is expressed as the per-
centage of Thioflavine-S-positive area over total area. C, D: Guanidine-extractable Ab40 (C) and Ab42 (D)
were measured by ELISA and normalized for total protein. The graphs correspond to 10 APP/PS1
(APP/BAC2) and 10 ABCA1/APP/PS1 (APP/BAC1) animals. E: PBS-soluble cortical apoE levels were
measured by ELISA and normalized for total protein. The graph represents two independent measurements
(each performed in triplicate) of ten APP/PS1 (APP/BAC2) and ten ABCA1/APP/PS1 (APP/BAC1)
animals. F: CSF cholesterol (Chol) levels were measured by Amplex Red assay in 20 APP/PS1 (APP/BAC2)
and eight ABCA1/APP/PS1 (APP/BAC1) mice. In all graphs, sample size is indicated by the num-
ber within the bar. Two-tailed Student’s t-tests were used for all statistical analyses. Values shown are
means 6 SEM.
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human ABCA1 mRNA levels relative to wild-type controls
(P. 0.05, n> 10) (Fig. 5C). Cerebellar ABCA1 protein lev-
els showed no significant difference in ABCA1 protein lev-
els among groups (P . 0.05, n > 8) (Fig. 5C).
ABCA1 expression is induced only in mice with
advanced disease
The results described above showing that ABCA1 mRNA
levels are increased in aged APP/PS1 mice suggest that
either ABCA1 may be induced in response to Ab or am-
yloid deposition or the that the presence of the APP/PS1
transgenes may alter ABCA1 expression even before am-
yloid neuropathology begins. To further determine the
relationship between ABCA1 expression and age, we ex-
amined ABCA1 expression in cortex and cerebellum of
young (2.7 6 0.24 months) and old (12.7 6 0.71 months)
APP/PS1 mice. Because the human ABCA1 BAC makes
little contribution to total ABCA1 mRNA levels in brain,
the animals used in this experiment were baseline APP/
PS1 mice on an F1 50% C3H, 50% C57Bl/6 genetic back-
ground, which is slightly different from the animals an-
alyzed above, on a 75% C57Bl/6, 25% C3H background.
As expected, murine abca1 mRNA levels were not in-
creased in 2.7 month old APP/PS1 cortex or cerebellum
compared with wild-type controls (P . 0.05, n > 4 for
each group) (Fig. 6A), demonstrating that ABCA1 is not
induced simply by expressing the APP and PS1 transgenes
before the initiation of amyloid deposition. Also as ex-
pected, APP/PS1 mice showed no increase in cerebellar
abca1 mRNA expression even at 12.7 months of age
(Fig. 6A, right panel). Unexpectedly, however, we did not
observe a significant induction in cortical abca1 mRNA
levels in 12.7 month old APP/PS1 mice (Fig. 6A, left
panel), in contrast with our observations in Fig. 5. No sig-
Fig. 3. Human ABCA1 expression in the cortex of APP/PS1 mice
is insufficient to increase total ABCA1mRNA or protein levels. A–C:
ABCA1 mRNA levels were determined using quantitative RT-PCR
using human-specific primers (A), murine-specific primers (B), or
primers that do not distinguish between species (C). Graphs are
expressed as fold difference of ABCA1/APP/PS1 (APP/BAC1)
mice relative to APP/PS1 (APP/BAC2) controls, which were as-
signed an arbitrary value of 1. Numbers in each bar represent the
number of independent animals that were analyzed, using at least
duplicate measurements per animal. D, E: ABCA1 protein levels
were evaluated by Western blot and normalized to GAPDH as
an internal loading control from $10 independent mice per
genotype. Two-tailed Student’s t-tests were used for all statistical
analyses. Values shown are means 6 SEM.
Fig. 4. Human ABCA1 expression in the liver of APP/PS1 mice
results in significant increases in total ABCA1 mRNA and protein
levels. A–C: ABCA1 mRNA levels were determined using quanti-
tative RT-PCR using human-specific primers (A), murine-specific
primers (B), or primers that do not distinguish between species
(C). Graphs are expressed as fold difference of ABCA1/APP/PS1
(APP/BAC1) mice relative to APP/PS1 (APP/BAC2) controls,
which were assigned an arbitrary value of 1. Numbers in each bar
represent the number of independent animals that were analyzed,
using at least duplicate measurements per animal. D, E: ABCA1
protein levels were evaluated by Western blot and normalized to
GAPDH as an internal loading control from eight independent
mice per genotype. Two-tailed Student’s t-tests were used for all
statistical analyses. Values shown are means 6 SEM.
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nificant difference in ABCA1 protein abundance in cortex
or cerebellum was observed in any group (P . 0.05, n > 4
mice/genotype) (Fig. 6B), consistent with themRNA results.
These data show that ABCA1 mRNA clearly is not in-
duced in mice before amyloid deposition. However, we
were surprised that abca1 mRNA levels were not increased
in the cortex of APP/PS1 mice at 12.7 months of age, be-
cause we had previously observed significantly increased
abca1 mRNA levels in APP/PS1 (APP/BAC2) cortex at
14.5 months of age, when each cohort was compared with
littermate controls appropriately matched for age as well
as genetic background. Notably, the difference in ages of
these two cohorts is statistically significant (P 5 0.002),
and Ab levels increase steeply in the APP/PS1 model over
the age ranges used in these experiments. Therefore, it is
possible that ABCA1 is induced only upon reaching a
threshold level of Ab that occurs between 12 and 14months
of age. Alternatively, it is possible that genetic background
also may affect the response of ABCA1 expression to amy-
loid pathology.
To determine whether Ab levels were indeed higher in
the cohort with increased abca1 mRNA levels, we directly
compared guanidine-extractable Ab levels in cortex and
cerebellum of 14.5 month old APP/PS1 (APP/BAC2)
mice on the 25% C3H, 75% C57Bl/6 background (re-
ferred to as group A or APP/BAC2) with those in
12.7 month old APP/PS1 animals on the 50% C3H, 50%
C57Bl/6 background (referred to as group B or APP/PS1)
(Fig. 7). Neither group for this analysis contained the
human ABCA1 BAC transgene. Cerebellum was examined
because it was negative for any changes in ABCA1 expres-
sion in all of the experiments described above, even
Fig. 5. Regional specificity of ABCA1 induction. A, B: Murine (A) and human (B) ABCA1 mRNA levels were determined in cortex
(amyloid-rich) and cerebellum (amyloid-poor) of wild-type, ABCA1 BAC, APP/PS1, and ABCA1/APP/PS1 mice using quantitative RT-PCR.
Graphs are expressed as fold difference of all groups relative to wild-type controls, which were assigned an arbitrary value of 1. Data
represent at least duplicate measurements for six to eight independent mice in each group. C: ABCA1 protein levels were evaluated by
Western blot and normalized to GAPDH as an internal loading control from eight or more independent mice per genotype for each group,
analyzed by one-way ANOVA. Data represent at least duplicate measurements per mouse. WT, wild type. Values shown are means 6 SEM.
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though the presence of the PS1DE9 mutation in the APP/
PS1 model of AD is associated with Ab and amyloid
accumulation in the cerebellum. Thioflavine-S staining
revealed that cerebellar amyloid deposits were present but
not as extensive as in cortex (data not shown). Ab40 levels
were significantly higher in group A or APP/BAC2 than in
group B or APP/PS1 animals for both cortex (P5 0.038, n
> 6) and cerebellum (P 5 0.037, n > 6). Furthermore,
cortex contained significantly more Ab40 than cerebellum
for both group A or APP/BAC2 (P , 0.0001, n > 6) and
group B or APP/PS1 (P 5 0.003, n > 6) mice. Similarly,
Ab42 levels were significantly higher in group A or APP/
BAC2 than in group B or APP/PS1 animals in cortex (P 5
0.039, n> 6) and cerebellum (P5 0.012, n> 6), and cortex
contained significantlymoreAb42 than cerebellum for both
group A (APP/BAC2) (P , 0.0001, n > 6) and group B
(APP/PS1) (P 5 0.0004, n > 6) mice. These results dem-
onstrate that evenmodest differences in age and/or genetic
background significantly influence Ab burden in the APP/
PS1 model. More importantly, because abca1 mRNA levels
were increased only in cortex of animals with the highest
Ab levels (groupA or APP/BAC2mice, 14.5months of age,
on a 25% C3H, 75% C57Bl/6 background), our results
suggest that ABCA1 mRNA may be induced only in re-
sponse to very advanced amyloid deposition.
Soluble apoE levels are increased in mice with
amyloid deposits
Because transcription of ABCA1 is clearly not impaired
in the amyloid-containing brain, posttranscriptional reg-
ulatory mechanisms may impose an upper limit on ABCA1
protein levels achievable in aged APP/PS1 mice with exten-
sive amyloid deposits. Wang et al. (30) previously reported
that apolipoproteins, including apoA-I and apoE3, stabi-
lize ABCA1 protein in primary macrophages, hepatocytes,
and transfected HEK cells. To determine whether apoE
levels may be limiting in the amyloid-containing brain, we
measured PBS-soluble and guanidine-insoluble apoE levels
in wild-type, ABCA1 BAC, APP/PS1, and ABCA1/APP/PS1
mice. Consistent with our previous observations (19), sol-
uble apoE levels were increased ?2-fold in the amyloid-
containing brain, and the presence of the ABCA1 BAC
did not affect this increase (n 5 10–13, P , 0.001) (Figs. 1
and 2). These data show that soluble apoE is present in
excess in the amyloid-containing brain, suggesting that
mechanisms other than apoE availability must contribute
Fig. 6. ABCA1 mRNA is not increased in baseline APP/
PS1 brains at ?3 (2.7 6 0.243) or ?13 (12.7 6 0.713)
months of age. A: Murine abca1 mRNA levels were deter-
mined in cortex and cerebellum using quantitative RT-
PCR in 3- and 13-month old mice (n = 6–7 mice/group).
Graphs are expressed as fold difference of all groups rel-
ative to wild-type controls at 3 months of age. B: ABCA1
protein levels were evaluated by Western blot and nor-
malized to GAPDH as an internal loading control from
four to six mice per group, analyzed by Student’s t-test.
Data represent at least duplicate measurements per mouse,
expressed relative to 3 month old wild-type (WT) mice that
were arbitrarily assigned an ABCA1 protein level of 100%.
Values shown are means 6 SEM.
Fig. 7. Ab40 and Ab42 levels are significantly influenced
by age and/or genetic background. Guanidine-extractable
Ab40 (A) and Ab42 (B) levels were determined by ELISA
in cohorts of APP/PS1 mice on a 25% C3H, 75% C57Bl/6
background at 14.5 months of age (group A) compared
with cohorts of APP/PS1 mice on a 50% C3H, 50% C57Bl/
6 background at 12.7 months of age (group B). Each data
point represents an individual mouse (group A cortex,
n5 18; group B cortex, n5 7; group A cerebellum, n5 17;
group B cerebellum, n 5 5).
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to the failure to observe increased ABCA1 protein levels in
brain regions rich in amyloid deposits.
DISCUSSION
ABCA1 is a critical regulator of apoE metabolism in the
CNS (8, 9). We and others have demonstrated that de-
ficiency of ABCA1 reduces the levels and lipidation of
apoE, which results in enhanced amyloidogenesis in vivo
(19–21). These findings raise the important question of
whether overexpression of ABCA1 can increase apoE lev-
els or lipidation and reduce amyloid burden. As a first step
toward addressing this question, we crossed ABCA1 BAC
Tg mice to the APP/PS1 model of AD and analyzed the
impact of human ABCA1 on amyloid deposition, Ab levels,
and apoE abundance. We specifically selected the ABCA1
BAC Tg model because it expresses human ABCA1 in a
physiologically accurate manner (22, 24) that has been
shown to be atheroprotective in vivo (25, 26). Further-
more, we confirmed that, in mice without amyloid de-
posits, ABCA1 BAC Tg mice exhibit a subtle 50% increase
in cortical ABCA1 protein and a very modest 15% increase
in cortical apoE protein compared with wild-type controls.
These data show that BAC RP11-32H03 supports a slight
but significant overexpression of ABCA1 in brain.
However, the presence of the ABCA1 BAC made no sig-
nificant impact on amyloid burden, Ab levels, apoE abun-
dance, or CSF cholesterol levels in aged APP/PS1 mice,
raising the question of whether the BAC transgene re-
mained functional in mice with amyloid deposits. Quan-
titative RT-PCR experiments demonstrated that human
ABCA1mRNA was clearly present in ABCA1/APP/PS1 and
not in APP/PS1 cortex, as expected. However, in amyloid-
containing cortex, BAC RP11-32H03 did not make a
significant contribution to the total ABCA1 mRNA pool;
therefore, no increase in ABCA1 protein levels was de-
tected. This is not attributable to a loss of global BAC
transgene expression, because, in these same animals,
human ABCA1 constituted a significant proportion of total
ABCA1 mRNA in liver and resulted in the expected in-
crease in liver ABCA1 protein levels in ABCA1/APP/PS1
mice compared with APP/PS1 controls.
Further analysis revealed that ABCA1 expression ap-
pears to be responsive to local signals that may be gen-
erated in brain regions containing extensive amyloid
deposits. Both human and murine ABCA1 mRNA levels
were increased in cortex but not in cerebellum of aged
ABCA1/APP/PS1mice, demonstrating regional specificity
in the ABCA1 transcriptional response. However, this local
induction of ABCA1 mRNA does not necessarily lead to
increased protein levels, as ABCA1/APP/PS1 mice, which
have the highest levels of ABCA1 mRNA, did not display a
proportional increase in cortical ABCA1 protein. In these
cohorts, a very subtle increase in cortical ABCA1 protein
was observed in the presence of the BAC transgene alone
or in mice containing amyloid deposits, but these levels
were not increased additively in mice with the BAC trans-
gene as well as amyloid deposits. These observations
suggest that ABCA1 may also be subject to posttranscrip-
tional regulatory mechanisms that may impose an upper
limit on the degree to which physiologically regulated
ABCA1 protein levels can be reached in brain regions that
are prominently affected in AD.
Furthermore, induction of ABCA1 transcription was
evident only in mice with the highest Ab and amyloid
burdens. ABCA1 mRNA levels were not increased before
amyloid deposition or in cohorts that contained abundant
Ab and amyloid load at 12.7 months of age. In contrast,
a separate cohort that was slightly older (14.5 months of
age) and had a 2-fold increase in Ab40 and Ab42 levels
did display a significant increase in ABCA1 transcription,
although we cannot rule out the possibility that genetic
background may also significantly influence ABCA1 ex-
pression. Even though we cannot distinguish between the
effects of genetic composition and age in this analysis, our
results clearly demonstrate that physiologically regulated
ABCA1 mRNA is induced only in advanced disease.
The mechanisms underlying this complex regulation of
ABCA1 expression in the amyloid-containing brain remain
to be completely defined. Transcription of ABCA1 is reg-
ulated by LXR/RXR agonists in both peripheral and CNS
cells (17, 18, 31). Two different subtypes of LXRs, LXRa
and LXRb, have been described (32). LXRa is expressed
at low levels in the CNS (33), whereas LXRb is expressed
broadly and at high levels in rodent brain (34–37). Among
LXRb ligands, 24S-hydroxycholesterol (24S-OH-Chol)
and 27-hydroxycholesterol (27-OH-Chol) have been im-
plicated in AD (38–40), and both are reported to induce
ABCA1 transcription (18, 41). 24S-OH-Chol is the major
cholesterol metabolite in brain and the primary route
of cholesterol egress from the CNS (42, 43). 24S-OH-Chol
is synthesized in the brain by cholesterol 24-hydroxylase,
which in humans is expressed nearly exclusively in neu-
rons (40, 42, 44, 45). In contrast, mice and rats generate
only 50% and 70% 24S-OH-Chol in the brain, respectively
(46, 47). 24S-OH-Chol levels in plasma and CSF are
reported to be increased in subjects with mild to moderate
AD (48–50), reflecting increased brain cholesterol turn-
over during the early stages of AD, when neurodegenera-
tion is beginning. In severe to end-stage AD, however,
extensive neuronal loss results in an eventual decline in
24S-OH-Chol levels in brain, CSF, and plasma (38, 40, 51).
In contrast, 27-OH-Chol is produced in most peripheral
cells (52), and the level of 27-OH-Chol in brain tissue is
normally so low that it is useful as a marker of increased
blood-brain barrier permeability and sterol influx into the
CNS. Notably, the levels of 27-OH-Chol have been re-
ported to be increased in postmortem human AD tissue
and in the APP23 model of AD at ages concomitant with
amyloid deposition (40), consistent with reports of blood-
brain barrier leakiness as an early feature of AD patho-
genesis (53). However, no differences were observed in
brain 24S-OH-Chol levels in aging APP23 mice (54), sug-
gesting either that changes during AD pathogenesis may
be too subtle to detect in mice that have a broader choles-
terol 24-hydroxylase distribution than humans or that the
lack of extensive neurodegeneration in many models of
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AD may result in little net change in 24-OH-Chol. Addi-
tional studies will be required to elucidate whether these
or other oxysterols may be involved in the transcriptional
response of ABCA1 to amyloid deposits.
ABCA1 expression is also regulated at the posttranscrip-
tional level. In cholesterol-loaded macrophages, ABCA1
is degraded by the proteasomal system in a process that
requires a functional Niemann-Pick type C gene (55). This
pathway may be relevant during neurodegeneration, when
increased free cholesterol is released from dying neurons
and scavenged by microglia. In addition, both unsaturated
and saturated fatty acids regulate ABCA1 protein stability
in vitro (56, 57). ABCA1 contains a PEST sequence from
amino acids 1,283–1,306 that modulates protein degrada-
tion by calpain (30). Residues tyrosine 1,286 and tyrosine
1,305 within the PEST sequence are normally constitu-
tively phosphorylated, which results in a rapid turnover
of ABCA1 in the absence of apolipoproteins. These resi-
dues become dephosphorylated in the presence of apoA-I
or apoE, which stabilize ABCA1 by inhibiting calpain-
mediated degradation (30, 58). We considered the possi-
bility that limited amounts of soluble apoE, the major
apolipoprotein in brain, may contribute to the lack of
ABCA1 protein accumulation when ABCA1 mRNA levels
are high. However, here we show that soluble apoE levels
are in fact increased 2-fold in cortex with extensive amy-
loid deposits. This observation suggests that mechanisms
other than apoE availability must contribute to the fail-
ure to accumulate high levels of ABCA1 protein in the
amyloid-containing cortex.
Our findings pose a potential challenge to the con-
sideration of using selective ABCA1 overexpression as a
therapeutic means to increase apoE levels or lipidation in
brains expected to develop AD neuropathology. Although
we show that excess physiologically regulated ABCA1 can
result in increased brain apoE levels, this was only ob-
served in animals without amyloid deposits. It remains to
be determined whether driving selective ABCA1 expres-
sion to much higher levels in the brain, for example using
exogenous nonphysiological promoters, can override the
regulatory mechanisms that appear to attenuate the
expression of ABCA1 protein in the amyloid-containing
brain and whether this will lead to increases in apoE levels
and lipidation that will be sustained in the presence of AD
neuropathology. Our study clearly demonstrates that phys-
iologically regulated excess ABCA1 is unable to mitigate AD
neuropathology in mice and suggests for the first time that
ABCA1 may also be subject to transcriptional and posttran-
scriptional regulation during the pathogenesis of AD.
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